ArticleScientific reports2025
The additive effect of hemoglobin glycation index and glycemic variability to predict mortality in cardiac intensive care patients with and without diabetes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hemoglobin glycation index (HGI) and glycemic variability (GV) are important metabolic markers associated with cardiovascular diseases and their prognoses. However, the potential additive effect of these biomarkers on mortality risk remains unclear. This study aimed to investigate the independent and combined effects of HGI and GV on mortality in cardiac ICU patients, both with and without diabetes. We conducted a retrospective cohort analysis of 1636 individuals admitted to the cardiac ICU. The primary outcome was 28-day mortality, with 365-day mortality as a secondary endpoint. Kaplan-Meier survival curves, Cox proportional hazards models, restricted cubic splines, receiver operating characteristic (ROC) curve, and subgroup analyses were used to evaluate the relationship between the HGI and adverse outcomes. During the follow-up period, 163 patients (10.0%) died within 28 days, and 322 patients (19.7%) died within 365 days. ROC analysis showed that the combination of HGI and GV had better predictive accuracy for mortality compared to HGI alone (28-day mortality: 0.658 vs. 0.621, P = 0.025; 365-day mortality: 0.644 vs. 0.562, P < 0.001) and GV alone (28-day mortality: 0.658 vs. 0.622, P = 0.036; 365-day mortality: 0.644 vs. 0.618, P = 0.031). Among non-diabetic patients, low HGI combined with high GV was linked to the highest mortality risk at both 28 days (HR = 4.223, 95% CI: 2.336-7.634) and 365 days (HR = 2.504, 95% CI: 1.550-4.045). However, diabetic patients with low HGI and low GV had the greatest risk of death at 28 days (HR = 3.729, 95% CI: 1.747-7.959) and 365 days (HR = 2.287, 95% CI: 1.324-3.951). The results suggested a potential additive effect of HGI and GV on mortality risk at both 28-day and 365-day in cardiac ICU patients, regardless of diabetes status. This combined biomarker approach may guide personalized glycemic management and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.